Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00291356 · ClinicalTrials.gov registry record · Phase 2
GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00291356 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 45 participants.
The verdict
NCT00291356, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a study to compare the safety, blood concentrations, and effects of GSK189075, GW869682, and placebo when dosed for 2-weeks by mouth to patients with type 2 diabetes.
Interventions
- DRUG GSK189075 oral tablets
- DRUG GW869682 oral tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00291356
The ClinicalTrials.gov registry entry for NCT00291356 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GSK189075 oral tablets is the first listed.
NCT00291356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00291356 about?
NCT00291356 is a clinical study titled "GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients". This is a study to compare the safety, blood concentrations, and effects of GSK189075, GW869682, and placebo when dosed for 2-weeks by mouth to patients with type 2 diabetes.
What is the current status of trial NCT00291356?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2006-01. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00291356?
The interventions under investigation include: GSK189075 oral tablets (DRUG), GW869682 oral tablets (DRUG).
Who is sponsoring clinical trial NCT00291356?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.